Rani Therapeutics Holdings Inc Cl A (RANI) Stock Price, Quote & News

Company Profile

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes...

Industry: Biotechnology

Sector: Healthcare

Phone: 408 457 3700

Website: www.ranitherapeutics.com

Address:

2051 Ringwood Avenue, San Jose, United States

sharetp02 Aug. 15 at 8:54 PM

$TNYA - my average is .88 and I'm debating if I should hang on or take profits. Usually, I'd hold but Ive not had luck with biotechs. S Personally, I like this biotech stock and it usually stays around 1.15+. However, I'm still hanging on to $RANI which continues dropping & no comments on $RVPH. Both are lost causes. Rani went up to 2.0 for a few hour but that was it. I'm still waiting on news on $ALLR, as I really like what the company id doing. Nobody has a crystal ball but will this rally continue Monday or will an overstuffed human whale decides to sell before that and stuff themselves again causing a panic which then everyone starts to sell😂🤔. Thoughts? Any analysis, opinions would be greatly appreciated. $TNYA

4 · Reply

Fishbonee Aug. 14 at 5:38 PM

$RANI

0 · Reply

logical_indian5 Aug. 13 at 7:19 PM

$RANI this company's product has immense potential because of how they can transform medications to a pill form. Particularly the GLP1s - that are currently only available as injectables. It is a shame that the company's management has been dragging their feet, and the GLPs are still only in preclinical and barely phase 1 trials. There does not seem to be any timeline either. Huge maybe, but if they are able to get something made within the next year and a half - this company could be valuable, but this is basically going to require at least 1 reverse stock split, and several raises in capital. Could see this falling significantly before it rises significantly. Such a shame that a good idea probably won't make it very far in the near future at least

0 · Reply

Fishbonee Aug. 13 at 1:42 PM

$RANI

0 · Reply

Tooneyman Aug. 13 at 12:01 AM

$RANI .... So when will this stock get the delisting warning from Nasdaq? Gotta be pretty soon ... ☹️

0 · Reply

ZacksSCR Aug. 12 at 2:52 PM

$RANI: Second Quarter Financial Results https://buff.ly/yWN3Mv7

0 · Reply

mikesterz7 Aug. 12 at 10:56 AM

$RANI Earnings surprise

0 · Reply

Fishbonee Aug. 12 at 12:52 AM

$RANI 📈

0 · Reply

Fishbonee Aug. 11 at 7:25 PM

$RANI

0 · Reply

BinaryLogic Aug. 9 at 6:11 PM

$RVYL $RANI [Again]

0 · Reply

Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update

Jul 15, 2025, 9:00 AM EDT - 4 weeks ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering

Jul 14, 2025, 5:00 AM EDT - 5 weeks ago

Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery

May 19, 2025, 8:00 AM EDT - 3 months ago

Rani Therapeutics Announces Research Agreement with Chugai

May 13, 2025, 4:05 PM EDT - 3 months ago

Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

Mar 31, 2025, 7:15 PM EDT - 4 months ago

Rani Therapeutics Holdings, Inc. (RANI) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 4:05 PM EDT - 5 months ago

Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

Mar 26, 2025, 4:05 PM EDT - 5 months ago

Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102

Mar 25, 2025, 6:00 PM EDT - 5 months ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Oct 15, 2024, 8:30 AM EDT - 10 months ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants

Oct 8, 2024, 4:05 PM EDT - 11 months ago

Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics to Participate in September Investor Conferences

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update

Jul 29, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics to Participate in August Investor Conferences

Jul 22, 2024, 8:30 AM EDT - 1 year ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment

May 14, 2024, 8:00 AM EDT - 1 year ago

Rani Therapeutics to Participate in May Investor Conferences

May 9, 2024, 8:00 AM EDT - 1 year ago

Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024

May 6, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update

Mar 20, 2024, 7:05 PM EDT - 1 year ago

Rani Therapeutics Holdings, Inc. (RANI) Q4 2023 Earnings Call Transcript

Mar 20, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update

Mar 15, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

Dec 14, 2023, 8:00 AM EST - 1 year ago

Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist

Nov 8, 2023, 4:05 PM EST - 1 year ago

Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update

Oct 19, 2023, 4:05 PM EDT - 1 year ago

Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study

Oct 12, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research

Sep 19, 2023, 6:36 AM EDT - 2 years ago

Rani Therapeutics: Excellent Technology But Major Risks Ahead

Sep 18, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)

Sep 7, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies

Aug 11, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update

Jun 21, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics' Presentation On Oral Delivery of PTH for Osteoporosis Named Presidential Poster Competition Winner at ENDO 2023 Annual Conference

Jun 8, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics Announces Acceptance of Late-Breaking Abstract of Oral Delivery of GLP-1 Agonist at the American Diabetes Association Annual Conference

Jun 5, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics and Celltrion Expand Partnership to Include Adalimumab Biosimilar for RT-105

Jun 1, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics to Present at the Jefferies Healthcare Conference

May 31, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics Announces Acceptance of Three Abstracts for Presentation at ENDO 2023 Annual Conference

May 24, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics Appoints Kate McKinley as Chief Business Officer

May 10, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics Reports First Quarter 2023 Financial Results; Provides Corporate Update

May 5, 2023, 5:33 PM EDT - 2 years ago

Rani Therapeutics: Novel Drug Delivery System, Under-Covered And Early Stage

Apr 11, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference

Mar 22, 2023, 6:43 PM EDT - 2 years ago

Rani Therapeutics Holdings, Inc. (RANI) Q4 2022 Earnings Call Transcript

Mar 22, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Corporate Update

Mar 16, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates

Jan 9, 2023, 8:30 AM EST - 2 years ago

Celltrion and Rani Therapeutics Partner on Development of Oral Monoclonal Antibody Treatment

Jan 5, 2023, 4:05 PM EST - 2 years ago

Rani Therapeutics Receives Feedback from Pre-IND Meeting with FDA; Provides Pipeline Update

Dec 6, 2022, 4:05 PM EST - 2 years ago

Rani Therapeutics Announces Repeat-Dose Topline Results from RT-102 Phase 1 Study

Nov 9, 2022, 4:05 PM EST - 3 years ago

Rani Therapeutics to Present at the Stifel Healthcare Conference

Oct 24, 2022, 8:30 AM EDT - 3 years ago

Rani Therapeutics Announces New RT-111 Development Program and Provides Corporate Update

Sep 6, 2022, 4:05 PM EDT - 3 years ago

Rani Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Aug 11, 2022, 11:47 PM EDT - 3 years ago

Rani Therapeutics Announces Termination of Public Offering of Class A Common Stock

sharetp02 Aug. 15 at 8:54 PM

4 · Reply

Fishbonee Aug. 14 at 5:38 PM

$RANI

0 · Reply

logical_indian5 Aug. 13 at 7:19 PM

0 · Reply

Fishbonee Aug. 13 at 1:42 PM

$RANI

0 · Reply

Tooneyman Aug. 13 at 12:01 AM

$RANI .... So when will this stock get the delisting warning from Nasdaq? Gotta be pretty soon ... ☹️

0 · Reply

ZacksSCR Aug. 12 at 2:52 PM

$RANI: Second Quarter Financial Results https://buff.ly/yWN3Mv7

0 · Reply

mikesterz7 Aug. 12 at 10:56 AM

$RANI Earnings surprise

0 · Reply

Fishbonee Aug. 12 at 12:52 AM

$RANI 📈

0 · Reply

Fishbonee Aug. 11 at 7:25 PM

$RANI

0 · Reply

BinaryLogic Aug. 9 at 6:11 PM

$RVYL $RANI [Again]

0 · Reply

scottm83 Aug. 8 at 12:07 AM

$RANI the news and earnings are great! It should run in the morning.

0 · Reply

Letsinvest2024 Aug. 5 at 6:41 PM

$RANI I’m asking all the 1012 watchers here, are you loading up? Based on Yahoo finance, it’ll hit $8 in a year. Too optimistic???

1 · Reply

scottm83 Aug. 4 at 12:47 AM

$RANI Positive news coming out this week

0 · Reply

Pharma_Stock_Calls Aug. 1 at 1:36 PM

✅ 💊 $RANI Entry: $0.5286 → Target: $0.66

0 · Reply

Pharma_Stock_Calls Jul. 30 at 5:10 PM

✅ 💊 $RANI Entry: $0.5570 → Target: $0.68

0 · Reply

lisaparsons Jul. 30 at 1:50 PM

$RANI guys and gals how long does rani have to maintain nasdaq compliance. ? thanks

1 · Reply

Pharma_Stock_Calls Jul. 29 at 6:15 PM

✅ 💊 $RANI Entry: $0.5371 → Target: $0.67

0 · Reply

Lillymilly Jul. 27 at 6:06 PM

$RANI Next week will be interesting. Some good news, Social Media buzz and retail frenzy can end with short squeeze.

1 · Reply

BNBComedian Jul. 26 at 7:22 PM

$RANI Got a tip on this, , whats the bull and bear thesis? Do people want to take robotic pills instead of a Q1W shot?

0 · Reply

scottm83 Jul. 26 at 4:11 PM

$RANI make that 5

0 · Reply

BinaryLogic Jul. 26 at 12:38 AM

$RVYL $RANI [Again]

1 · Reply

scottm83 Jul. 24 at 9:26 PM

$RANI looking good again 4 straight days on the rise

0 · Reply

Market Cap	34.76M
Revenue (ttm)	1.03M
Net Income (ttm)	-30.02M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,914.56%
Debt to Equity Ratio	-3.91

Volume	711,714
Avg Vol	2,184,190
Day's Range	N/A - N/A
Shares Out	63.21M
Stochastic %K	63%
Beta	-0.02
Analysts	Strong Sell
Price Target	$7.80